Ireland C M
Children's Leukemia and Cancer Research Unit, Prince of Wales Children's Hospital, New South Wales, Australia.
Cancer Res. 1989 Oct 15;49(20):5530-3.
Fifteen primary neuroblastomas and four bone marrow samples from neuroblastoma patients, representing clinical Stages I to IV, have been screened for mutations in codons 12, 13, and 61 of N-ras. Neuroblastoma DNAs were subjected to the polymerase chain reaction to amplify the relevant sequences and were then hybridized with specific oligonucleotides to locate and identify point mutations. The results show that one Stage I tumor contained an N-ras gene that was activated by a GC-CG transversion of the first base of codon 61, while in one Stage II tumor, activation of N-ras involved a GC-CG transversion of the first position of codon 13. N-ras activations were not detected in the six Stage III tumors and eight Stage IV tumors that were examined.
对15例原发性神经母细胞瘤以及4例神经母细胞瘤患者的骨髓样本（代表临床I至IV期）进行了N-ras基因第12、13和61密码子突变的筛查。将神经母细胞瘤DNA进行聚合酶链反应以扩增相关序列，然后与特定寡核苷酸杂交以定位和鉴定点突变。结果显示，1例I期肿瘤含有一个通过密码子61第一个碱基的GC-CG颠换而激活的N-ras基因，而在1例II期肿瘤中，N-ras的激活涉及密码子13第一位的GC-CG颠换。在所检测的6例III期肿瘤和8例IV期肿瘤中未检测到N-ras激活。
